Table 2.

Demographic and Clinical Characteristics of Patients Receiving Buprenorphine (January 2015 to December 2017) Related to Retention in December 2018 (n = 238)

VariableRetained N = 82 n [%]Dropped N = 156 n [%]χ2 ortP
Age, years, mean (SD)37.4(11.5)34.4(10.6)−1.98.049
Marital status.66
 Single, never married63[78]125[81]
 Divorced, separated, or widowed4[5]5[3]
Insurance coverage<.001
 Other insurance31[38]49[32]
Comorbid conditions
 Chronic pain17[21]17[11]4.25.039
 Personality disorder5[6]5[3]1.12.29
 Mood stabilizers6[7]9[6]0.21.64
 Other antidepressants17[21]24[15]1.08.30
Smoking status (n = 237)11.40.003
 Current smoker50[60]125[81]
 Former smoker16[20]14[9]
 Never smoker16[20]15[10]
Continuity of care, mean (SD)0.70(0.12)0.61(0.24)−3.87<.001
Seen by behavioral health23[28]24[15]5.44.019
Buprenorphine status at first visit2.16.34
 New induction17[21]38[24]
  • ADHD, attention deficit hyperactivity disorder; PTSD, posttraumatic stress disorder; SSRI, selective serotonin reuptake inhibitor; SNRI, selective norepinephrine reuptake inhibitor; SD, standard deviation.

  • Independent samples t-test were used to examine differences in continuous variables (signified by mean, SD) by retention status; χ2 tests were used to examine differences in categorical variables by retention status. The retained category includes 6 patients who died during the study observation period and are censored in the survival analysis. For variables with cells < 5, a Fisher’s exact test was used to calculate the P-value (marital status, insurance type, benzodiazepine prescription, and psychosis). For tables larger than 2 × 2, SAS uses a Monte Carlo simulation to estimate the P-value in Fisher’s exact tests.